EU/3/15/1521

About

On 28 July 2015, orphan designation (EU/3/15/1521) was granted by the European Commission to Dr Ulrich Granzer, Germany, for artesunate for the treatment of malaria.

The sponsorship was transferred to B And O Pharm, France, in June 2020.

Key facts

Active substance
Artesunate
Disease / condition
Treatment of malaria
Date of first decision
28/07/2015
Outcome
Positive
EU designation number
EU/3/15/1521

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

B And O Pharm
Zac De La Masquere
500 Rue De L Hers
31750 Escalquens
France

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating